CJC-1295
Other ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Synthetic long-acting GHRH analog studied in healthy adults for GH/IGF-1 stimulation. It is not an FDA-approved wellness therapy, and FDA flags serious adverse events and limited clinical data.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
CJC-1295 is an other most often used for no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. NutriStack rates the overall evidence as insufficient. A typical adult dose is Not provided; NutriStack does not provide dosing guidance for research peptides., commonly taken as not supported for human use outside approved clinical research or regulated medical care. This profile indexes 3 sources.
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
The bottom line
Evidence rating insufficient. Most-documented uses: no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. 3 sources indexed (2006–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Acts as a GHRH receptor agonist and can raise growth hormone and IGF-1. This endocrine activation creates clinically meaningful safety uncertainty outside supervised research.1,2
Dosing & protocol.
Route-specific guidance is intentionally not provided for unapproved research peptides.
Full safety detail.
Side effects
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
Contraindications
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
- Use by competitive athletes subject to anti-doping rules
- Use without clinician supervision
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsSource linkedPMIDTeichman SL et al. · J Clin Endocrinol Metab · 2006
CJC-1295 produced prolonged GH and IGF-1 stimulation in healthy adults, supporting pharmacologic activity but not wellness use.
- 2Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogSource linkedPMIDIonescu M, Frohman LA · J Clin Endocrinol Metab · 2006
Small human endocrine study; not evidence of long-term safety or clinical benefit for consumer use.
Reference material
1- 3Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA identifies immunogenicity/impurity concerns, limited clinical data, and serious adverse events including increased heart rate and systemic vasodilatory reaction.
Common questions.
Quick answers about CJC-1295, drawn from the data on this page.
What is CJC-1295?
Synthetic long-acting GHRH analog studied in healthy adults for GH/IGF-1 stimulation. It is not an FDA-approved wellness therapy, and FDA flags serious adverse events and limited clinical data.
What is CJC-1295 used for?
Commonly cited benefits of CJC-1295 include: No approved wellness use; Human efficacy evidence is insufficient for consumer guidance; Reference-only safety profile. NutriStack rates the overall evidence as insufficient.
What is a typical dose of CJC-1295?
A typical adult dose of CJC-1295 is Not provided; NutriStack does not provide dosing guidance for research peptides.. The commonly recommended form is Not supported for human use outside approved clinical research or regulated medical care. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of CJC-1295?
Reported side effects include unknown product purity, potency, and sterility risk outside regulated drug supply, injection-site reactions or infection risk with injectable products, immune reactions are possible with peptide impurities or aggregation. This is educational information; check with a healthcare professional before use.
How strong is the evidence for CJC-1295?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
CJC-1295 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.